Navigation Links
Novel drug holds promise for treatment of Rheumatoid Arthritis

The successful completion of Phase II clinical trials of a novel drug called dnaJP1 for treatment of osteoarthritis that works without suppressing the immune system has been announced by Researchers at the University of California//.

Rheumatoid arthritis is a chronic, painful disease affecting millions worldwide. It is thrice more common in women in men and affects people of any age. It strikes joints on both sides of the body, such as the hands or feet or knees but can also affect the skin, eyes, lungs, heart, blood, nerves or kidneys. It is an incurable disease, with most therapies focusing on symptom relief.

Current medications for treating RA range from anti-inflammatory drugs, such as aspirin, to corticosteroids and medicines that alleviate symptoms by suppressing or killing the body’s immune response, basically crippling the body’s ability to defend itself against other infectious diseases or cancer.

The novel drug is a peptide derived from a naturally occurring protein, dnaJ, which generates inflammation in RA patients. The drug when administered disturbs the immune system, which is then activated to kill and clear foreign pathogens in the body. This results in an enhanced immune response which is not possible otherwise. The drug would have to administered through the oral route as the immune set up in the gut has the potential to educate the body to view a protein as one that isn’t dangerous or foreign. DnaJP1 was found effective in a double-blind, placebo-controlled trial sponsored by the National Institutes of Health, which took place between 2000 and 2005 and involved about 160 patients.

Patients received 25mg of dnaJP1 daily by mouth for six months, and the treatment was found to be safe and well-tolerated. When compared with a placebo, patients in the treatment group experienced lessening of symptoms such as swollen joints, tenderness, pain and decreased mobility. Improvement was particularly significant at the fol low up visits, indicating a lasting effect of the drug.

The first two trials of dnaJP1 have not raised any significant safety concerns and offer an improved treatment option for patients with rheumatoid arthritis, especially while taking into consideration the side effects associated with current available therapy. The researchers intend to get approval and funding to move into Phase III clinical trials.

This is a very exciting and novel therapeutic approach, which holds the promise to be an entirely new type of immunomodulatory drug – one that can shape a patient’s immune system, rather than suppressing it. With such an advance, the treatment of rheumatoid arthritis seems a potential reachable realit.
'"/>




Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
8. Novel Therapy for Chronic Problem
9. Blood Sugar Kept In Control By Novel Protein
10. Novel antibiotic dressing developed for improved wound healing
11. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s 2016 Executive Forum, taking ... of the country’s top healthcare executives to share insights on transformational strategies to ... Forum is the provider-centric perspective, experience, expertise and strategy shared by the participants,” ...
(Date:2/10/2016)... MA (PRWEB) , ... February 10, 2016 , ... Gout ... switch, and brings pain that is often severe, with intense swelling and redness. It ... than eight million people, but older adults are the most susceptible, according to the ...
(Date:2/10/2016)... ... ... Armune BioScience signed a definitive agreement with ARCpoint Labs ... country. Launched in April of 2015, Apifiny is the only cancer specific, non-PSA blood ... exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized Apifiny to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric ... in their patients. Research shows that the Goal Attainment Scale (GAS) captures 20% ... this challenge and learn more about the Goal Attainment Scale, Education Resources Inc. ...
(Date:2/10/2016)... ... February 10, 2016 , ... A ... Safety Congress and Expo event March 9-11, 2016. Hosted by Ohio's Bureau of ... , As the longest running and largest worker's compensation event in Ohio, ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... LONDON , February 10, 2016 ... 2016, which will be held at Victoria Park Plaza in ... host an informative seminar on technology and future advances for ... seminar, led by Lorna Graham , associate director of ... technology to keep up with new regulations and standards in ...
(Date:2/10/2016)... ATLANTA , Feb. 10, 2016  LexisNexis® ... and technology, today announced the launch of ... analytics solution that helps improve and optimize the ... evaluation of performance using severity-adjusted scores. By measuring ... a critical solution to deliver better outcomes, improve ...
(Date:2/10/2016)... SAN DIEGO , Feb. 10, 2016 ... biopharmaceutical company developing novel, clinical-stage therapies for sickle cell ... an underwritten public offering of 29,090,910 units at a ... unit consists of one share of the Company,s common ... the Company,s common stock at an exercise price of ...
Breaking Medicine Technology: